iBio Inc IBIO.OQ IBIO.O is expected to show a rise in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Bryan Texas-based company is expected to report revenue of $25 thousand, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for iBio Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 23.7% in the last three months.
Wall Street's median 12-month price target for iBio Inc is $5.00, about 72.2% above its last closing price of $1.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.39 | -0.36 | -0.49 | Missed | -34.2 |
Mar. 31 2025 | -0.32 | -0.49 | Missed | -53.1 | |
Dec. 31 2024 | -0.46 | -0.46 | -0.48 | Missed | -4.3 |
Sep. 30 2024 | -0.53 | -0.48 | -0.46 | Beat | 4.2 |
Jun. 30 2024 | -0.47 | -0.47 | -0.91 | Missed | -92.8 |
|
This summary was machine generated November 7 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)